

//  
//  
//

( )

\*

---

:

:

( )

( )

CCI

$5-7 \times 10 \text{ L/m}^2$

$10 \times 10 \text{ L/m}^2$

:

:

:

---

:

:

---

*m-ilkhani@yahoo.com* :

...

:

:

:

:

:

:

:

HLA

( )

( )

HLA

\* /L

(% ) HLA

%

(% ) %

\* /L

( )

\*

%

$\times \left( \frac{\quad}{10^{11} \times} \right) = \text{CCI}$

$10^{11} \times$

HLA-DR

\* /L

CCI

\* /L

HLA

%

( )

:

HLA

/ /

/ /

/

)

)

(

(

( )

( )	( )		
/	/	( )	•
( )	(%)	:	•
( / )	( / )		%
( / )	( )	ALL	•
( / )	(%)	AML	•
( / )	( )		•
( / )	( )		•
/ ± /	/ ± /		•
/ ± /	/ ± /		•
		:	•
/			•
	/		•

CCI

%

)

(  
P < /

(% ) (P < / P < / )  
(% / )

/

( )

%

%

.( )

% /

%

( )

% /

## **REFERENCES**

---

2. Barz D, Staack D, Lehmann R, Stange K, Schnurstein K. Antibody formation after filtered blood cell replacement in hematologic-oncologic patients. *Beitr Infusionsther Transfusionsmed* 1996; 33: 30-4.
3. Balducci L, Benson K, Lyman GH, Sanderson R, Fields K, Ballester OF, et al. Cost-effectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia. *Transfusion* 1993; 33(8): 665-70.
4. Hoffman R. *Hematology: Basic principles and practice*. USA: Churchill Livingstone, 1991.
5. Sniecinski I, O'Donnell MR, Nowicki B, Hill LR. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. *Blood* 1988; 71(5): 1402-7.